The Conversation (0)
HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results
Mar. 23, 2018 08:45AM PST
Genetics InvestingHTG Molecular Diagnostics (Nasdaq:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today reported its financial results for the fourth quarter and year ended December 31, 2017. As quoted in the press release: “We entered 2017 with specific goals to accelerate customer adoption, expand our BioPharma pipeline, initiate commercialization of our CE/IVD products …
HTG Molecular Diagnostics (Nasdaq:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today reported its financial results for the fourth quarter and year ended December 31, 2017.
As quoted in the press release:
“We entered 2017 with specific goals to accelerate customer adoption, expand our BioPharma pipeline, initiate commercialization of our CE/IVD products in Europe and strengthen our balance sheet. 2017 exceeded our performance expectations, and we move into 2018 looking forward to continuing our momentum,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics.